Across TCGA pan-cancer cohorts, SDE2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SDE2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SDE2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SDE2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
COAD and UCEC are the cancer types where SDE2 Mutation most reproducibly stratifies survival.